scholarly journals P203 Sexual Dysfunction in Chronic Inflammatory Bowel Disease: Myth or Reality?

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S266-S266
Author(s):  
A Hassine ◽  
A Hammami ◽  
W Ben Ameur ◽  
W Dahmani ◽  
N Elleuch ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Sexual Dysfunction ◽  
Disease Activity ◽  
Bowel Disease ◽  
Severe Disease ◽  
Chronic Inflammatory Bowel Disease ◽  
Cross Sectional ◽  
Significant Difference ◽  
Inflammatory Bowel ◽  
Chronic Inflammatory Bowel

Abstract Background Sexual dysfunction is often associated with impaired body image and quality of life in patients. However, little data exists on sexual dysfunction (SD) in patients with Chronic Inflammatory Bowel Disease (IBD). The aim of this study was to assess the prevalence and risk factors for sexual dysfunction in patients with IBD. Methods This is a cross-sectional study of all patients followed for IBD. Sexual function was assessed by the Female Sexual Index Function (FSIF) for women and the International Index of Erectile Function (IIEF) for men. Sexual dysfunction was confirmed when the total FSIF score was less than 26, or the IIEF score less than 26. Crohn’s disease (CD) activity was assessed by the Harvey-Bradshaw index (HBI), and that of ulcerative colitis (UC), by the clinical Mayo scores. Results We collected 100 patients, with a mean age of 42.18 ± 15.71 and a sex ratio (M / F) = 1.5. Sixty eight patients had CD and 32 patients had UC. Ano-perineal manifestations were present in 38.2% of cases. Severe disease activity was noted in 14 patients (20.6%) with CD and 10 patients (31.3%) with UC. Twelve patients had proctitis. 38% of patients had surgical treatment: 18.75% for patients with UC and 47.05% for those with CD. Total colectomy was performed in 12% of cases. At the time of the study, 20% of patients were on systemic corticosteroid therapy, 22% on Azathioprine, 4% on Salazopyrine, 8% on 5-ASA and 46% on Anti-TNFα. Sexual dysfunction was reported by 42.9% of women: 57.14% (UC) vs 38.46% (CD) (p = 0.042). On the other hand, sexual dysfunction was reported by 27.6% of men: 22.2% of men with UC and 28.57% with CD, with no statistically significant difference (p = 0.78). A significant association was found between sexual dysfunction and the degree of disease activity (p <0.001 for CD, p = 0.003 for UC), as well as pancolitic involvement in women with UC (p = 0.002). However, the presence of anoperineal manifestations, rectal involvement and history of surgery were not significantly associated with the frequency of sexual disturbances. Conclusion Our study showed a high prevalence of sexual dysfunction in patients with IBD. Training gastroenterologists in the management of sexual dysfunction would make it possible to satisfy patient expectations.

scholarly journals P209 Prevalence and risk factors for fatigue in chronic inflammatory bowel disease

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S269-S270
Author(s):  
A Hassine ◽  
A Hammami ◽  
A Braham ◽  
H Jaziri ◽  
A Jmaa
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Severe Disease ◽  
Cross Sectional Study ◽  
Chronic Inflammatory Bowel Disease ◽  
Cross Sectional ◽  
Inflammatory Bowel ◽  
Chronic Inflammatory Bowel

Abstract Background Fatigue is one of the most common symptoms reported by patients with chronic inflammatory bowel disease (IBD), being in flare or in remission. Thus, several fatigue measurement tools have been developed. The objective of our work was to assess the prevalence of fatigue in patients with IBD and its impact on daily life, and to determine its risk factors. Methods This is a cross-sectional study of patients followed for IBD who presented to our consultation during the three months preceding the study. Fatigue assessment was performed by IBD-F score (The Inflammatory Bowel Disease Fatigue Self-assessment Scale). The higher the score, the more disabling the fatigue. The activity of Crohn’s disease (CD) was assessed by the Harvey-Bradshaw index (HBI), that of ulcerative colitis (UC) by the clinical Mayo score. Results One hundred patients were included. Thirty-two patients (32%) had UC and 68 patients (68%) had CD. The mean age was 42.18 years [16–81 years], with a predominance of men (sex ratio = 1.5). Severe disease activity was noted in 14 patients (20.6%) with CD and 10 patients (31.3%) with UC. Extra-intestinal manifestations, particularly articular, were noted in 20% of cases. 36% of patients were in clinical remission. The prevalence of fatigue was 94.11% in MC and 93.75% in RCH. Fatigue was noted in 83.3% of patients in remission.Fatigue was severe (section I score between 11 and 20) in 40% of patients. We found a significant association and a linear correlation between the presence and severity of fatigue and CD activity (p <0.001, r = 0.84), as well as UC activity (p <0.001, r = 0.74). A significant association was found with extra-intestinal manifestations (p = 0.028), as well as with the presence of other chronic diseases (p = 0.014). In 30% of cases, fatigue was responsible for a functional handicap (section II score between 61 and 120). This effect was also strongly correlated with disease activity: MC (p <0.001, r = 0.74) and RCH (p <0.001, r = 0.73). Conclusion Assessing the severity of fatigue and its impact on the daily activities of patients is a crucial pillar in the management of patients with IBD. In our series, the prevalence of fatigue was 94%. It was associated and correlated with the degree of disease activity.

scholarly journals FRI0476 RHEUMATIC MANIFESTATIONS DURING INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 835.2-835
Author(s):  
M. Boudabbous ◽  
H. Gdoura ◽  
L. Chtourou ◽  
A. Amouri ◽  
L. Mnif ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Chronic Inflammatory Bowel Disease ◽  
Canadian Association ◽  
Rheumatic Manifestations ◽  
Significant Difference ◽  
Inflammatory Bowel ◽  
Chronic Inflammatory Bowel

Background:Rheumatologic manifestations are frequent extraintestinal manifestations (MEI) of chronic inflammatory bowel disease (IBD). Some of these manifestations develop in parallel with the underlying disease, others evolve on their own account. They sometimes lead to reconsider the initial therapy for intestinal purposes.Objectives:The aim of our study is to specify the epidemioclinical characteristics of osteoarticular manifestations of chronic inflammatory bowel disease and their possible impact on intestinal diseaseMethods:This is a retrospective study conducted between January 2000 and December 2015 including patients hospitalized in our department for chronic inflammatory bowel disease (IBD).Results:During the study period, 206 patients with IBD were hospitalized in our department, 78 of whom had rheumatic MEI (frequency equal to 37.8%). These 78 patients were divided into 48 men and 30 women with a sex ratio of 1.6 and an average age of 40.7 ± 13.6 years (18–79). They had Crohn’s disease in 60% of the cases. The average length of service for IBDs was 83 ± 73 months (4–360). Osteoarticular MEIs were peripheral in 56.4% of cases, axial in 29.5% of cases, mixed in 6.41% of cases with the presence of osteopenia in 6.41% of cases and osteoporosis in 1 28%. The activity of IBD associated with these MEI was moderate with an average number of outbreaks / year of 1.6 ± 0.8. These patients were treated with salicylates in 30.7% of the cases using corticosteroid therapy at least once in 23% of the cases. Maintenance treatment based on immunosuppressants was found in 38.46% of cases and anti-TNF alfa in 10.25% of cases. During follow-up, 3 patients died (3.84%). There was no significant difference between patients with IBD with rheumatic MEI and without rheumatic MEI regarding epidemiological data and disease activity.Conclusion:Rheumatic MEIs are found in almost 40% of IBDs. They affect men more frequently than women and Crohn’s disease than UC. They are rather peripheral and do not associate with a more important activity of the disease.References:[1]Journal of the Canadian Association of Gastroenterology, 2019, 2(S1), S73–S80 doi: 10.1093/jcag/gwy053 Supplement ArticleDisclosure of Interests:None declared

scholarly journals P252 Medication adherence in inflammatory bowel diseases in the era of biotherapies

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S291-S291
Author(s):  
A Hassine ◽  
A Hammami ◽  
W Ben Ameur ◽  
W Dahmani ◽  
N Elleuch ◽  
...  
Keyword(s):  
Disease Activity ◽  
Treatment Adherence ◽  
Severe Disease ◽  
Treatment Compliance ◽  
Therapeutic Education ◽  
Chronic Inflammatory Bowel Disease ◽  
Cross Sectional ◽  
Significant Difference ◽  
Inflammatory Bowel ◽  
The Mean

Abstract Background Failure or poor adherence to therapy is a general problem ofpublic health, particularly common in chronic inflammatory bowel disease (IBD). In these pathologies, good compliance is, however, one of the keys to obtaining remission and in preventing relapses and complications. The objective of this study was to assess treatment compliance in our patients followed for IBD. Methods We conducted a single-center cross-sectional study, including all patients with IBD, who presented to our consultation during the three months preceding the study. We used the Morisky questionnaire to assess treatment adherence. This was considered low if the score is less than 6, medium if the score is between 6 and 8, and good if the score is equal to 8. Results We collected 100 patients, average age of 42.18 ± 15.71 years and a sex ratio (M / F) = 1.5. Sixty eight patients (68%) had CD and thirty two patients (32%) had UC. The mean duration of IBD progression was 9.02 ± 6.57 years. Anoperineal lesions were present in 38.2% of cases. Fourteen patients (20.6%) followed for CD and ten patients (31.3%) with UC had severe disease activity. The history of surgical resection was noted in 18.75% of patients followed for UC and 47.05% of those followed for CD. Extensive ileal resection was noted in 6.5% of patients with CD. At the time of the study, 20% of patients were on systemic corticosteroid therapy, 22% on Azathioprine, 4% on Salazopyrine, 8% on 5-ASA and 46% on Anti-TNFα in combination therapy. The mean Morisky score was 6.78 ± 1.31. Adherence to treatment was poor in 42% of cases, average in 34% of cases, and good in 24% of cases. Good treatment adherence was observed in 34.78% of patients taking Anti-TNFα vs. 14.81% in other patients with no statistically significant difference (p = 0.077). Morisky score was correlated with age (p = 0.032, r = 0.38). In addition, no significant association was found, with the duration of evolution (p = 0.75), the existence of other chronic diseases (p = 0.3), the number of outbreaks of IBD (p = 0.52), and disease activity (p = 0.38 for CD, p = 0.22 for UC). Conclusion The overall rate of treatment non adherence in IBD patients was significant in our series. It concerns nearly one in two patients. Prescribing Anti-TNFα does not appear to improve compliance. The integration of therapeutic education into our therapeutic strategy should be an asset major in improving treatment adherence.

Sign in / Sign up

Export Citation Format

Share Document